Tema Oncology ETF Rating → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free CANC Stock Alerts $27.06 -0.15 (-0.55%) (As of 03:56 PM ET) Add Compare Share Share RatingsStock AnalysisChartDividendHoldingsRatingsTrendsStock AnalysisChartDividendHoldingsRatingsTrends Tema Oncology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy2.72Holdings in CANC have an aggregate rating of Moderate Buy based on 501 analyst ratings issued in the past year covering 42 companies (81.6% of the portfolio).CANC Aggregate Price Target$40.9050.64% UpsideHigh Prediction$53.76Average Prediction$40.90Low Prediction$28.49Holdings in CANC have an aggregate price target of $40.90 and a range of $28.49 to $53.76 covering 42 companies (81.6% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy12 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 42 CANC Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.70%REGNRegeneron Pharmaceuticals$1,036.62-0.8%4 of 5 stars2.77$998.09 -3.7%22Analyst ForecastInsider Selling5.34%MRKMerck & Co., Inc.$127.73+0.2%4 of 5 stars2.69$133.00 4.1%13Analyst Forecast3.28%AMGNAmgen$306.06+0.9%5 of 5 stars2.52$305.85 -0.1%21Short Interest ↓3.10%ILMNIllumina$108.31-0.7%5 of 5 stars2.29$158.14 46.0%21Gap Up3.04%INCYIncyte$61.62-1.7%5 of 5 stars2.44$73.69 19.6%18Analyst Forecast2.93%RVMDRevolution Medicines$37.72+1.7%4 of 5 stars3.10$43.20 14.5%10Positive News2.85%BPMCBlueprint Medicines$106.58+2.6%1 of 5 stars2.63$108.00 1.3%162.81%MREOMereo BioPharma Group$3.96-6.8%2 of 5 stars3.25$7.33 85.2%4Gap Up2.80%ARGXargenx$378.98+0.2%3 of 5 stars2.80$520.68 37.4%20Analyst ForecastAnalyst Revision2.72%MRNAModerna$133.39-3.3%4 of 5 stars2.24$129.02 -3.3%172.57%EXELExelixis$21.64-0.6%5 of 5 stars2.59$26.13 20.7%17Positive News2.51%NTLAIntellia Therapeutics$24.81-1.4%3 of 5 stars2.69$64.75 161.0%13Analyst ForecastAnalyst Revision2.41%GMABGenmab A/S$25.85+0.3%3 of 5 stars2.38$49.25 90.5%13Positive NewsHigh Trading Volume2.35%GILDGilead Sciences$62.89-2.1%5 of 5 stars2.35$83.69 33.1%17Short Interest ↑2.33%CRSPCRISPR Therapeutics$60.81-1.6%1 of 5 stars2.35$75.71 24.5%17Analyst Forecast2.33%AGIOAgios Pharmaceuticals$42.21-0.9%3 of 5 stars2.50$50.67 20.0%4Analyst Forecast2.26%CLDXCelldex Therapeutics$34.75-0.5%1 of 5 stars2.83$63.00 81.3%7Analyst ForecastShort Interest ↓Gap Up2.25%GHGuardant Health$29.93-1.9%4 of 5 stars2.86$36.91 23.3%14Positive News2.12%BGNEBeiGene$154.66-3.0%2 of 5 stars2.80$251.93 62.9%10Short Interest ↓Positive News2.00%EXASExact Sciences$41.94+1.5%4 of 5 stars2.92$93.07 121.9%13Gap Up1.99%LEGNLegend Biotech$40.57-2.2%2 of 5 stars3.00$81.67 101.3%13Analyst ForecastNews Coverage1.75%NUVLNuvalent$78.28+1.4%1 of 5 stars2.90$90.78 16.0%10Positive News1.74%LNTHLantheus$81.67-1.2%4 of 5 stars2.86$99.17 21.4%7Positive News1.68%DAWNDay One Biopharmaceuticals$13.41+11.5%3 of 5 stars2.86$37.67 180.9%7Positive News1.46%MRUSMerus$54.23-2.8%3 of 5 stars3.00$73.60 35.7%12Analyst Forecast1.40%SWTXSpringWorks Therapeutics$36.29-1.0%1 of 5 stars3.00$68.83 89.7%6Positive News1.40%SDGRSchrödinger$19.31-2.9%1 of 5 stars2.67$40.89 111.7%91.23%BMYBristol-Myers Squibb$40.76-0.5%5 of 5 stars2.11$60.00 47.2%19Dividend AnnouncementAnalyst Downgrade1.21%RCUSArcus Biosciences$16.02-1.1%2 of 5 stars2.88$40.50 152.8%81.07%ACLXArcellx$53.84+0.2%2 of 5 stars3.07$78.00 44.9%14Short Interest ↑1.02%ARVNArvinas$24.99+0.2%3 of 5 stars2.88$61.13 144.6%16Short Interest ↓Positive News0.97%RLAYRelay Therapeutics$7.03-0.8%2 of 5 stars3.00$22.80 224.3%7Short Interest ↓Gap Up0.92%OPCHOption Care Health$28.08-1.5%5 of 5 stars3.00$40.00 42.5%3Positive News0.90%CGEMCullinan Therapeutics$16.94-10.9%2 of 5 stars3.00$32.00 88.9%6Short Interest ↑Gap Up0.88%IMCRImmunocore$35.90-2.9%2 of 5 stars2.87$81.85 128.0%15Short Interest ↑0.87%IDYAIDEAYA Biosciences$37.36-0.5%4 of 5 stars3.00$48.27 29.2%13Positive News0.83%COGTCogent Biosciences$8.40-4.5%1 of 5 stars2.71$14.67 74.6%7Analyst ForecastShort Interest ↑News Coverage0.56%JANXJanux Therapeutics$40.49+1.0%3 of 5 stars2.88$66.29 63.7%8Positive News0.56%CRBPCorbus Pharmaceuticals$43.87-0.8%5 of 5 stars3.00$69.33 58.0%3Gap Down0.55%CGONCG Oncology$34.10+1.1%1 of 5 stars3.00$63.75 87.0%4Positive News0.49%TXG10x Genomics$19.82-0.8%5 of 5 stars2.54$46.62 135.2%13Positive NewsGap Up0.39%FATEFate Therapeutics$3.31-7.3%4 of 5 stars2.21$6.75 103.9%14Analyst UpgradeShort Interest ↑News CoveragePositive NewsGap Up This page (NASDAQ:CANC) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
